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identify B-cell lymphoma drivers in mice
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B-cell lymphoma (BCL) is the most common hematologic malignancy. While sequencing
studies gave insights into BCL genetics, identiﬁcation of non-mutated cancer genes remains
challenging. Here, we describe PiggyBac transposon tools and mouse models for recessive
screening and show their application to study clonal B-cell lymphomagenesis. In a genome-
wide screen, we discover BCL genes related to diverse molecular processes, including
signaling, transcriptional regulation, chromatin regulation, or RNA metabolism. Cross-species
analyses show the efﬁciency of the screen to pinpoint human cancer drivers altered by
non-genetic mechanisms, including clinically relevant genes dysregulated epigenetically,
transcriptionally, or post-transcriptionally in human BCL. We also describe a CRISPR/Cas9-
based in vivo platform for BCL functional genomics, and validate discovered genes, such
as Rfx7, a transcription factor, and Phip, a chromatin regulator, which suppress lymphoma-
genesis in mice. Our study gives comprehensive insights into the molecular landscapes of
BCL and underlines the power of genome-scale screening to inform biology.
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B-cell lymphoma (BCL) accounts for a considerable numberof cancer cases1, with more than 300,000 new patients peryear worldwide2. Diffuse large B-cell lymphoma (DLBCL)
is the most common form of BCL. Patients with this aggressive
disease are often diagnosed at advanced stages3. Next-generation
sequencing (NGS) studies have given comprehensive insights into
BCL genetics4–9 but also revealed that the molecular basis of the
disease is still only partly understood. For example, it is still
challenging to pinpoint drivers among the thousands of epigen-
etically, transcriptionally, or post-transcriptionally dysregulated
genes in human BCL.
Insertional mutagenesis screens using retroviruses or DNA
transposons can overcome some of these limitations of classic
approaches to cancer genome analysis, particularly with regard to
the analysis of the non-mutated cancer genome10,11. Sleeping
Beauty (SB) and PiggyBac (PB) transposition systems originate
from transposable elements in the genome of salmonid ﬁsh12 and
the cabbage looper moth Trichoplusia ni13, respectively. Engi-
neering of modiﬁed transposon versions allowed their application
in mammalian systems, including germline manipulation14–17
and insertional mutagenesis in mice18–22. Transposon mutagen-
esis has been extensively used in the hematopoietic system to
discover novel cancer genes in various entities, including
acute23,24, and chronic25,26 leukemia. However, only few data are
available on lymphomagenesis27. Whole-body PB mutagenesis,
for example, only rarely induces BCL20 and could so far not be
deployed for BCL screening. SB and PB are complementary tools
with many different properties regarding cargo capacity, local
hopping tendency, integration preferences, and other
features11,28. As a consequence, screens performed with the two
systems identify not only common but also many non-redundant
genes18–20,22,29.
Cytogenetic studies and retroviral insertional mutagenesis
unraveled many of the key oncogenes driving B-cell
lymphomagenesis30,31. Examples are BCL2, BCL6, and MYC,
which have been extensively studied mechanistically32. In con-
trast, the role of tumor suppressors is generally less well under-
stood. To address this need, we developed transposition systems
for tumor suppressor screening in mice. Thereby, insertional
mutagenesis is achieved by mobilization of promotor-less trans-
posons carrying bidirectional gene trapping cassettes. We
expected this system to be very efﬁcient for the discovery of
haploinsufﬁcient tumor suppressor genes (TSG). However,
insertions of transposons in both alleles of a gene is extremely
unlikely to occur in the same cell, making recessive screening
a challenge. In human cancer evolution, mutation in one allele
of a tumor suppressor is often followed by loss of the wild-
type allele, e.g., through deletion or mitotic recombination.
To model and accelerate this process in mice, we took
advantage of the hypomorphic Bloom allele (Blmm3)33. The
Bloom syndrome RecQ-like DNA helicase contributes to the
maintenance of genomic integrity through its involvement in
the homologous recombination pathway34. Blmm3/m3 mice dis-
play highly elevated LOH rates through sister chromatid
exchange or copy number variation33,35–37. Hence, we aimed at
exploiting this model for recessive screening in the context
of transposon mutagenesis. Another limitation of whole-body
transposon screens is that BCL phenotypes are only rarely
induced. Blmm3/m3 mice are prone to B-cell lymphomagenesis33,
thus overcoming this problem.
Here, we combine the Blmm3/m3 allele with an inactivating PB
transposon system in mice to achieve genome-wide TSG
screening in BCL. We identify known and novel DLBCL genes,
validate selected candidate genes through a CRISPR/Cas9-based
functional approach and show the clinical relevance of our
ﬁndings using large human DLBCL patient cohorts.
Results
Development of inactivating transposon systems in mice. A
critical parameter affecting the success of TSG screens is the
efﬁciency of gene inactivation. Intragenic transposon insertions
are typically located in introns, which are much larger than exons.
To achieve gene inactivation from intronic positions, transposons
have to be designed to carry gene trapping elements. We ﬁrst
thoroughly tested different widely used splice acceptors (SA) at
the Hprt locus. Efﬁcient gene trapping at this X-chromosomal
locus confers 6-thioguanine (6TG) resistance in mouse embryo-
nic stem (ES) cells derived from male mice. Using recombinase-
mediated cassette exchange, we shuttled different transposon
variants carrying the adenovirus-derived SA (Av-SA), the
Engrailed-2 exon-2 SA (En2-SA), and the carp β-actin SA (Cβa-
SA) to the Hprt locus and selected cells for 6TG resistance
(Supplementary Figure 1). Trapping efﬁciencies were quantiﬁed
by counting 6TG-resistant colonies and were highest for the Av-
SA and the En2-SA.
Based on these results, we designed two transposon variants
(ITP1 and ITP2) that can inactivate genes independently of
their orientation (Fig. 1a). Both transposons contain PB and SB
inverted terminal repeats (ITR), allowing mobilization by either
transposase. Between the ITRs, they harbor bidirectional poly-
adenylation signals (pA), which are ﬂanked by the Adv-SA and
En2-SA. Additionally, ITP1 contains a bGEO (β-galactosidase
expression and neomycin resistance) reporter gene, which
enables visualization of gene-trapping events. We used these
constructs to generate ﬁve different transgenic transposon mouse
lines, which differ in the location of the transposon concatemer
and its size (2–70 transposon copies) (Fig. 1b). For subsequent
experiments, we selected the ITP1-C and ITP2-M lines, which we
intercrossed with iPBase knock-in mice (Rosa26PB/+, expressing
the insect version of the PB transposase constitutively; Fig. 1c),
and Blmm3/m3 mice (Fig. 1c). We observed pronounced
embryonic lethality in ITP1-C;Rosa26PB/+;Blmm3/m3 mice, with
only 6.0% of the expected triple-transgenic mice being born.
In contrast, ITP2-M;Rosa26PB/+;Blmm3/m3 mice were born in
proportions closer to the calculated Mendelian frequency (45.7%)
(Supplementary Data 1). These variations in embryonic lethality
are most likely due to the different transposon copy numbers
of the ITP1-C (70 copies) and ITP2-M (35 copies) lines.
IPBmice predominantly develop BCL. We used the ITP2-M line
to establish the screening cohorts, consisting of 123 experimental
ITP2-M;Rosa26PB/+;Blmm3/m3 mice (hereafter referred to as IPB)
and 87 Rosa26PB/+;Blmm3/m3 or ITP2-M;Blmm3/m3 control mice
(for tumor spectrum see Supplementary Table 1). Animals were
aged and monitored for tumor development. We observed a
broad spectrum of cancer phenotypes in both cohorts, but
tumor latency and survival was reduced substantially in IPB
mice (Fig. 1d, e). We collected tumors from 82 animals and
characterized them histopathologically. Roughly two-thirds of
tumors were hematopoietic neoplasms (n= 65), whereas 35%
constituted a broad range of solid cancers (n= 35; Supplementary
Figure 2; Supplementary Table 2). We characterized 59 hemato-
poietic tumors using an immunohistochemistry (IHC) panel
comprising the markers B220 (speciﬁc for B cells), CD3 (T cells),
myeloperoxidase (myeloid cells), and CD138 (plasma cells). The
vast majority of tumors were B cell neoplasms (52/59; 88.1%).
Only six CD3 positive T-cell lymphomas (10.2%) and one tumor
with myeloid differentiation (1.7%) were found.
Histopathological and molecular characterization of BCLs.
BCLs were almost exclusively reminiscent of human DLBCL (51/
52; 98.1%; Fig. 2a; Supplementary Data 2). Neoplasms usually
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manifested in mesenteric lymph nodes and/or spleens, with
moderate or extensive alterations of lymphoid organ architecture
due to abnormal B cell expansion (demonstrated using B220
IHC). DLBCLs were composed of large-sized neoplastic cells
(centroblasts) with abundant cytoplasm, a round nucleus, vesi-
cular chromatin, with two or more nucleoli, which were often
membrane-bound, and showed high proliferation rates (as
demonstrated by Ki-67 IHC).
In all tumors, we also observed a small percentage of lymphoid
cells with immunoblastic morphology (larger cells with abundant
cytoplasm and a single prominent centrally localized nucleolus).
A subset of DLBCL cases showed characteristics of plasmacytic
differentiation (13/51; 25.5%), in which a fraction of tumor cells
lost the B cell marker (B220) and expressed the plasma cell
marker (CD138) (Supplementary Figure 3). A signiﬁcant
proportion of tumor cells, however, retained B220 expression,
distinguishing these cancers from plasmablastic lymphoma or
other plasma cell malignancies. In general, tumor cell inﬁltration
into organs located within the thoracic and abdominal cavities,
such as lungs, liver, intestine, and kidneys was frequently
observed (37/42 analyzed DLBCLs; 88.1%; Supplementary Data 2)
while bone marrow inﬁltration was rare (2/42; 4.8%; Supplemen-
tary Figure 4).
To sub-classify the DLBCL cases based on their cell of origin,
we performed IHC using the germinal center marker Bcl6 and the
post-germinal center marker Mum1/Irf4. Expression of MUM1/
IRF4 is associated with non-germinal center B-cell like (GCB)
DLBCL in humans38. In contrast, BCL6 expression is primarily
associated with GCB DLBCL, although a subset of non-GCB
DLBCL is also positive for BCL639. We analyzed 20 samples and
found that 15 cases (75%) were Bcl6-positive/Irf4-negative,
suggesting a GCB DLBCL phenotype. Five cases (25%) were
Irf4-positive/Bcl6-negative, which we classiﬁed as non-GCB
DLBCL (see representative images in panels 4 and 5 of Fig. 2a).
In addition, we performed RNA sequencing of DLBCL samples
(n= 25) for gene-expression proﬁling (GEP), which is considered
the gold standard for DLBCL sub-classiﬁcation in humans39
(Fig. 2b). Using the murine orthologues of the human classiﬁer
genes40, mouse DLBCLs fell into two main clusters. Cluster B
contained exclusively IHC-diagnosed GCB tumors, whereas all
ﬁve IHC-diagnosed non-GCB cancers fell into cluster A (Fig. 2b).
As in human DLBCL, IHC-based and GEP-based tumor
classiﬁcation are not fully superimposable41. In fact, the
discordance in mice might be even stronger because mouse
DLBCLs are less homogeneous: we observed that GCB tumors
often contain inﬁltrates of CD3-positive T lymphocytes and
residual plasma cells, which makes accurate GEP from whole
tumor lysates challenging. This might be a reason why some of
the IHC-diagnosed GCB samples fall into cluster A. Taken
together, these data show that mouse DLBCLs can be sub-
classiﬁed similarly to human DLBCLs. Thus, our model
recapitulates key aspects of the human disease.
B-cell receptor repertoire proﬁling of DLBCLs. For clonality
analysis, we performed RNA-based immunoglobulin repertoire
proﬁling of 30 DLBCL cases (Fig. 3a; Supplementary Data 3). To
this end, we conducted full-length ampliﬁcation of the variable
regions of the immunoglobulin heavy (IGH) and immunoglo-
bulin light (IGL) chains. To eliminate PCR and sequencing errors
leading to incorrect clone assignments, unique molecular identi-
ﬁers (UMI) were introduced during cDNA synthesis. Immune
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repertoires were sequenced on the Illumina MiSeq. Data analysis,
de-multiplexing and UMI consensus sequence assembly was
performed with MIGEC42. MiXCR was used for clone detection
based on the highly variable complementarity-determining region
3 (CDR3)43. To visualize the clonal structure of tumors, we
developed CloNet, a pipeline for generation of clonality network
plots (Fig. 3a, b, Supplementary Figures 5, 6, 7 and 8). In these
plots, each clone constitutes a node of the network. The size of the
node correlates with the number of reads assigned to it, and
clones differing by only 1 bp in their CDR3 sequence are linked
by edges. The complexity of the branching (i.e. number of sub-
clones) is a measure for the grade of somatic hypermutation
(SHM), which is a hallmark of DLBCL44. We highlighted clones
that consist of more than 10% of the total reads of a sample in
color (red, blue, or green). Different clones (as deﬁned by a
unique V(D)J rearrangement) are marked with different colors.
Note that RNA was isolated from whole tumor tissue lysates
that contain varying amounts of non-transformed B cells (most
likely accounting for the small gray nodes in the plots). Figure 3c
shows the proportion of DLBCL cases with different grades of
clonality. The vast majority of tumors (16/26) were monoclonal,
indicating that these were full-blown malignant lymphomas
arising from one transformed B cell. Eight samples consisted of
two dominant clones, suggesting the presence of two independent
malignant DLBCLs in one mouse, and only two tumors arose
from multiple unrelated clones. We found evidence of SHM in
the majority of tumors (Fig. 3b). As expected, there were differ-
ences in the extent of SHM between individual tumors, and
between heavy and light chains of the same clone, as these
undergo SHM separately.
Characterization of DLBCLs by copy number analysis. To
further characterize DLBCLs, we carried out array comparative
genomic hybridization, which revealed recurrent ampliﬁcations
on chromosome 11qA1-B1.3 (10/16 samples; 62.5%; Fig. 4a, b).
The 5.6 Mb large minimal overlap region (chr11:21888515-
27523873) contains 27 protein-coding genes, including two well-
known DLBCL oncogenes Bcl11a and Rel, as well as other genes
with predicted oncogenic function, like Commd1 and Otx145,46.
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The concordant region in the human genome, 2p15-16, is fre-
quently ampliﬁed in human DLBCL cases47, demonstrating
again the relevance of our model, which recapitulates one of the
characteristic oncogenic events in human B-cell lymphomagen-
esis. Nevertheless, in contrast to human DLBCLs, which often
show multiple copy number alterations48, recurrently ampliﬁed/
deleted regions in the murine DLBCL cases were infrequent. This
suggests that transposon-driven mutagenesis is the key cancer-
promoting factor driving lymphomagenesis, removing the need
for such events, as also shown in previous transposon mutagen-
esis studies for osteosarcoma49.
QiSeq identiﬁes cancer genes in DLBCL. We performed quan-
titative transposon insertion site sequencing (QiSeq)28 in 42
DLBCL cases (Fig. 4a and Supplementary Data 2) and recovered
a total of 298,439 non-redundant insertions (supported by a
minimal read coverage of 2, which was set as threshold for call-
ing). Global analysis of insertion density/direction proﬁles
showed no preference for a speciﬁc transposon orientation, which
is in accordance with ITP2’s bidirectional gene inactivating cap-
ability (Fig. 4c). To detect genomic regions that are more fre-
quently hit by the ITP2 transposon than expected by chance, we
applied CIMPL50 (Common Insertion site Mapping Platform;
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based on a Gaussian kernel convolution framework), as well as
TAPDANCE51 (Transposon Annotation Poisson Distribution
Association Network Connectivity Environment; Supplementary
Data 4) analyses. The semi-quantitative nature of QiSeq allowed
us to set read-coverage-based thresholds for CIMPL analysis,
which identiﬁed 184 common insertion sites (CIS) when ana-
lyzing insertions with a read coverage ≥ 20 (n= 43,474 non-
redundant insertions; Supplementary Data 5; for co-occurrence
analysis see Supplementary Table 3). Transposon insertions in
CIS genes had typically no orientation bias and were distributed
over the whole length of the genes. Examples for such gene
inactivating insertion patterns, which predict a tumor suppressive
function for target genes, are shown in Supplementary Figure 9. A
few exceptions involving oncogene activation (e.g., by 3′ UTR
interference or cryptic activation) are displayed in Supplementary
Figure 10 for Malt1 and Rel.
Figure 4d shows the top 50 CIS genes identiﬁed in the screen.
Among them, 22 are either found in the Cancer Gene Census
database and/or have known roles in human DLBCL, while 28
genes have not yet been linked to B-cell lymphomagenesis.
Examples for the former include Pten, a major negative regulator
of the Pi3k/Akt/Mtor signaling pathway, which mediates signals
downstream of the B-cell receptor, and Gna13, for which
inactivating mutations have recently been discovered in follicular
lymphoma and DLBCL52,53.
We next explored globally possible functions linked to our top
50 CIS genes. As expected, Reactome gene set enrichment
analysis (using the top 50 genes as input) revealed enrichment of
signatures typical for DLBCL, including “immune system” and
“signaling mediated by the B-cell receptor” (Supplementary
Data 6). To gain deeper insights into known or predicted/
suspected molecular functions of the top 50 genes, we performed
systematic literature search. As indicated in Fig. 4d, we identiﬁed
genes with diverse molecular functions, including chromatin and
transcriptional regulators (22/50), signaling mediators (13/50),
and regulators of RNA metabolism (7/50).
We compared these CISs to the top 150 driver genes identiﬁed
in the largest available human DLBCL sequencing study (n=
1001 cases)4. We found that while some CIS genes (13/50; 26%)
are recurrently mutated (point mutations, indels) in the human
DLBCL dataset, the vast majority of genes (37/50; 74%) is not. We
therefore hypothesized that these unidentiﬁed genes are (i) not
recurrently mutated, (ii) part of the non-mutated DLBCL genome
altered by mechanisms other than mutation, such as transcrip-
tional or epigenetic dysregulation, or (iii) large deletions/
ampliﬁcations harboring hitherto unknown cancer genes. To
examine this possibility, we compared expression of genes in
DLBCL samples relative to non-malignant B cells (centroblasts)
(Fig. 5 and Supplementary Figure 11). Notably, human
orthologues of mouse CIS genes were highly signiﬁcantly
enriched among the genes downregulated in human DLBCL
(p= 5.7 × 10−16, Fisher’s exact test; Fig. 5). In addition, analysis
of copy number variation in human DLBCLs revealed almost
exclusively deletions at loci harboring human orthologues of
mouse CIS genes (Supplementary Figure 12). These cross-species
comparisons provide further support for the power of the screen
to identify tumor suppressors regulated in human DLBCL.
Loss of heterozygosity in tumors originating from IPB mice.
The necessity to inactivate TSGs biallelically poses a major
challenge for recessive screening approaches. In transposon
mutagenesis screens, the likelihood of both alleles of a TSG being
independently hit by two transposons in the same cell is extre-
mely small. To overcome this problem, we performed the screen
in a Blmm3/m3 background, which we hypothesized to enhance
LOH rates at CIS loci. To examine whether LOH is indeed
increased at TSGs hit by transposons, we analyzed the locus
of Pten, which is one of the top CIS genes in the screen. One
important consideration is that insertions can be subclonal, and
in such cases bulk-sequencing-based LOH studies are not possi-
ble. To address this issue, we exploited the semi-quantitative
nature of our insertion site sequencing approach (QiSeq), which
allowed us to draw conclusions about the clonal representation of
any given transposon integration. For LOH studies, we only used
cancers with high-coverage Pten insertions, suggesting their
presence in the major tumor clone. Ten such samples were
available. None of them displayed focal Pten deletions, and only
one high-coverage Pten insertion was observed per sample, sug-
gesting that transposon-based Pten inactivation is mono-allelic.
To examine the presence or absence of LOH, we ﬁrst
performed single nucleotide polymorphism (SNP) analysis using
amplicon-based NGS of the 10 DLBCL tissues and corresponding
tail samples from IPB mice (Fig. 6a). In six animals, a
heterozygous Pten germline variant was identiﬁed in the tail,
allowing SNP-based LOH proﬁling at this locus. In three out of
these six DLBCL cases, the heterozygous SNP was detected at
similar variant frequencies in DLBCL tissue and tail, indicating
either a lack of LOH in the tumor sample or a false-negative
result due to contaminating non-tumor cells in the tissue
(Fig. 6b). In the other three DLBCLs, variant frequencies deviated
substantially from 0.5, clearly demonstrating LOH at the Pten
locus (Fig. 6b). Thus, LOH occurred in at least 50% of those
tumors in which LOH analysis was possible. We also observed
LOH at other loci, such as the Apc gene in an IPB small intestine
tumor (Supplementary Figure 13), showing that LOH is not
restricted to the Pten locus.
Fig. 3 Clonality analysis of DLBCLs by immune repertoire sequencing. a Workﬂow for B-cell receptor repertoire analysis. Full-length ampliﬁcation and
sequencing of immunoglobulin heavy and light chain variable regions was performed from bulk tumor tissue (n = 30) of ITP2-M;Rosa26PB/+;Blmm3/m3 (IPB)
mice. Top image shows exemplary cDNA product after library preparation with ampliﬁed variable and constant region of the immunoglobulin heavy chain
(light gray). Unique molecular identiﬁers (UMI; green) and adapters and barcodes for sequencing (dark gray) were introduced during library preparation.
Dotted arrows indicate reads for 300 bp paired-end sequencing. Sequenced raw reads were de-multiplexed and a consensus read sequence for each UMI
was assembled with MIGEC. All reads containing an identical UMI were collapsed into one read. MiXCR was used for mapping of reads to mouse reference
sequences and clonotype assembly based on the complementarity-determining region 3 (CDR3) region. To visualize the clonal structure of individual
tumors, we developed CloNet, a pipeline for generation of clonality network plots. b Exemplary clonality network plots derived from four different mouse
DLBCL samples. Plots display clonal structures of immunoglobulin heavy and light chains. Each clone (deﬁned by a unique CDR3 sequence) constitutes a
node of the clonality network. The size of the node scales with the third root of the count of the reads assigned to it. A link between two nodes was drawn if
the clones mapped to identical V and J genes and differed by at most 1 bp in their CDR3 sequence. The complexity of the branching of a clone (i.e. number
of subclones) is a measure for the grade of somatic hypermutation. Clones deﬁned by a unique V(D)J rearrangement that contained more than 10% of the
total reads are highlighted in color. Two monoclonal (IPB_10.6c and IPB_11.4c) samples, one biclonal (IPB_10.3c) and one oligoclonal (IPB_1.5c) sample are
shown. c Proportion of monoclonal (1 clone), biclonal (2 clones), and oligo-/polyclonal (>2 clones) DLBCL samples. BC barcode, V variable gene segment,
NDN diversity gene segment, J joining gene segment, C constant gene segment, HC heavy chain, LC light chain, Tr total reads, Cf fraction of clone
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To examine LOH in samples where SNP-based LOH analysis
was not possible (no heterozygous germline variants at the locus
of interest), we also scored Pten expression by IHC in the 10 IPB
DLBCLs with high-coverage Pten insertions (Fig. 6c). The vast
majority of samples (8/10) had lost Pten expression (scored as
“negative” or “weak”), indicating LOH in the tumors.
We next examined if the hypomorphic Blmm3/m3 context is
associated with increased LOH rates at CIS genes. To this end, we
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took advantage of a similar whole-body screen, which we
performed in Blm-proﬁcient mice. A critical consideration is
that many tumor suppressors can act in a haploinsufﬁcient
manner, which might be cell/entity-speciﬁc. For example, it is
known that Pten can act as a haploinsufﬁcient TSG, but is also
frequently inactivated homozygously in various cancer types.
Little is known how the cellular/entity-context affects either
scenario. We therefore considered it essential to look at the same
entity when performing comparative LOH analyses in Blmm3/m3-
and Blm-proﬁcient screens. In Blm-proﬁcient mice BCLs are rare,
but the large size of the screen (n= 256 tumors) allowed us to
collect a sufﬁcient number of DLBCLs (n= 7) for such analyses.
All seven DLBCLs had high-coverage Pten insertions, making
them suitable for side-by-side comparisons with corresponding
Pten-altered lymphomas in the Blmm3/m3 cohort.
We performed IHC-based semi-quantitative assessment of Pten
expression and found that the majority of Blm-proﬁcient DLBCLs
(5/7) expressed substantial Pten levels, ruling out the possibility of
homozygous Pten inactivation and LOH in these samples (Fig. 6c).
In contrast, among the above described Blmm3/m3 DLBCLs,
only 2/10 showed signiﬁcant Pten expression, suggesting that
LOH was much more common (p= 0.03, Fisher’s exact test).
Altogether, these data support a model in which the Blmm3/m3
context elevates LOH at CIS genes, thereby facilitating recessive
screening.
CRISPR/Cas9-based in vivo validation of candidate genes. To
validate cancer genes emerging from our screen, we ﬁrst per-
formed in vitro competition assays using DLBCL cell lines, but
did not observe signiﬁcant effects upon candidate gene knock-
down (Supplementary Figure 14). Functional gene validation in
full-blown cancer cell lines can however be substantially limited
by various factors, including (i) the wrong genetic, mutational, or
cell-of origin context in which a gene of interest is operative,
(ii) the highly abnormal genome and aggressive nature of full-
blown cancer cells, often precluding the detection of subtle phe-
notypes, (iii) the restricted set of readouts in vitro, which do not
encompass the large spectrum of possible cancer-driving pro-
cesses affected by a gene, or (iv) inherent differences between
in vitro and in vivo situations. To overcome these and other
limitations related to in vitro validation experiments in cancer cell
lines, we developed an efﬁcient in vivo approach for BCL func-
tional genomics. To this end we combined Eµ-myc mice (a well-
established model system for B-cell lymphomagenesis54) with a
Cas9 knock-in mouse line (Rosa26Cas9 mice; Fig. 7a), which we
generated in C57BL/6 JM8 ES cells (Supplementary Figure 15) to
support syngeneic transplantation experiments. We isolated
E13.5 fetal liver cells from Eµ-myc;Rosa26Cas9 mice as a source of
hematopoietic stem and progenitor cells (HSPC), and manipu-
lated them ex vivo using CRISPR/Cas9. HSPCs were put into
short-term culture and infected with a GFP-tagged lentiviral
vector containing a single guide RNA (sgRNA) cassette. Cas9
expression from the Rosa26 knock-in allele substituted for viral
Cas9 delivery. The small cargo size of sgRNA-only viral vectors
allowed us to produce high viral titers and achieve high trans-
duction rates (typically around 20%; Supplementary Figure 16).
This was the key step for accomplishing an efﬁcient validation
platform, as we had only been able to achieve transduction rates
of ~1% when using all-in-one (Cas9 plus sgRNA) lentiviral vec-
tors. HSPCs were then used for reconstitution of irradiated
C57BL/6 recipient mice. We monitored transplanted animals
until appearance of signs of sickness and/or tumor development.
To validate our model, we ﬁrst performed side by side targeting
of Trp53 by CRISPR/Cas9 and RNAi in Eµ-myc;Rosa26Cas9
HSPCs (Fig. 7b). We observed signiﬁcantly accelerated lympho-
magenesis in recipients transplanted with Trp53-sgRNA HSPCs
or Trp53-shRNA HSPCs as compared to mice receiving HSPCs
transduced with non-targeting sgRNA (control mice). Further-
more, lymphoma development occurred signiﬁcantly earlier
in the Trp53-sgRNA group (CRISPR/Cas9 knockout) as com-
pared to the Trp53-shRNA (knockdown) group, reﬂecting
gene-dosage effects.
Fig. 4 Genetic analysis of DLBCLs. a Scheme of experimental and analytic workﬂow. b Overlay of copy number proﬁles showing cancer-relevant
ampliﬁcations/deletions in 16 DLBCLs from ITP2-M;Rosa26PB/+;Blmm3/m3 (IPB) mice. A zoomed-in view is provided for Chr11, which harbors frequent
ampliﬁcations (identiﬁed in mouse GCB as well as ABC DLBCLs). The minimal ampliﬁed region contains—among other genes—the known DLBCL
oncogenes Bcl11a and Rel. c Circos plot visualizing transposon insertion data from 42 IPB-DLBCLs. Rings from inward to outward: Insertion density plot for
both orientations (shown in blue and green), number of insertions per common insertion site (CIS; dark yellow bars; axis from 0 to 140), number of
contributing samples per CIS (red bars; axis from 0 to 40). Top 50 CIS genes are annotated. d Top 50 CIS genes ranked by number of contributing DLBCL
samples. Molecular function (determined by literature search) of CIS genes is indicated. Transcription factors constituted the largest functional gene class
(n= 15). Compared to the total number of mouse transcription factors (n= 1603), the enrichment for transcription factors among the top 50 CIS genes
is highly signiﬁcant (p= 1.4 10−5, Fisher’s exact test). Genes present in Cancer Gene Census (CGC) database and/or known for their role in DLBCL
(literature search) are represented in dark blue, unknown DLBCL genes by light blue boxes. QiSeq quantitative transposon insertion site sequencing, aCGH
array comparative genomic hybridization
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The strikingly high number (22/50; 44%) of genes involved in
transcriptional regulation and chromatin organization identiﬁed
in our screen prompted us to validate two candidate tumor
suppressor genes linked to these functional groups: Regulatory
factor X7 (Rfx7) and Pleckstrin homology domain interacting
protein (Phip). Both genes are substantially downregulated in
human DLBCL as compared to non-malignant B cells (Fig. 5).
RFX7 is a member of the RFX transcription factor family
with unknown function. Transposon insertion patterns in Rfx7
suggest a tumor suppressive function (Fig. 7c). In line with
this observation, rare truncating mutations in RXF7 have
been reported in human BCL9,55 (Supplementary Figure 17).
CRISPR/Cas9 targeting of Rfx7 in HSPCs conﬁrmed its predicted
function as a DLBCL tumor suppressor (Fig. 7d; Supplementary
Figure 18a). Mice transplanted with Rfx7-sgRNA transduced
Eµ-myc;Rosa26Cas9 HSPCs showed signiﬁcantly accelerated
lymphomagenesis. In particular, whereas all (5/5) animals in
the Rfx7-sgRNA group developed BCLs between 64 and 109 days
post transplantation (pt), only one (1/9) control mouse was
diagnosed with BCL at 129 days pt (Fig. 7d). Sequencing of
the Rfx7 target region in Rfx7-sgRNA tumors showed clonal
frameshift-inducing insertions/deletions (indels) ranging from
1 bp to 5 bp (Supplementary Figure 19a) and real-time quanti-
tative PCR (qPCR) revealed a signiﬁcant reduction of Rfx7
expression (Supplementary Figure 18b).
PHIP is a bromodomain-containing protein expressed in a
wide range of tissues, including B cells. Its molecular function has
not been studied so far, but an association with melanoma
progression and oncogenic effects has been reported recently56.
The transposon insertion pattern in our mouse cancers predicts
however that gene-inactivation is the cancer-causing mechanism
(Fig. 7e), suggesting a role of Phip as a tumor suppressor in
DLBCL. To examine whether PHIP is relevant to human BCL,
we analyzed publicly available genomic datasets derived from
human BCL cases. Single nucleotide variants were rare across
different studies, although occasional truncating mutations were
observed9,55,57 (Supplementary Figure 17). For one dataset copy
number data derived from SNP arrays is available (TCGA-DLBC;
TCGA Research Network: http://cancergenome.nih.gov). Figure 7f
shows the type and frequency of copy number variation at human
chromosome 6 (the home of PHIP) in DLBCL. Focal or arm-
level Chr6q loss is frequent in human DLBCL, with several
minimal commonly deleted regions, of which one affects PHIP.
We therefore sought to functionally validate Phip using the
CRISPR/Cas9-based approach described above. We found that
mice receiving Eµ-myc;Rosa26Cas9 HSPCs transduced with a
Phip sgRNA (Supplementary Figure 16) presented signiﬁcantly
accelerated BCL development (Supplementary Figure 18a),
with an onset ranging from 47 to 130 days pt (Fig. 7g and
Supplementary Figure S19b). Moreover, BCLs harvested from
these animals showed signiﬁcantly reduced Phip expression
(Supplementary Figure 18b). We thus conclude that PHIP is a
target gene in the minimal deleted region on chromosome 6
in human DLBCL. Altogether, these data validate Rfx7 and Phip
as potent tumor suppressors in B-cell lymphomagenesis.
Clinical relevance of the identiﬁed tumor suppressor genes.
To investigate if TSGs from the top 50 CIS list can be used as
predictive markers in human DLBCL, we systematically analyzed
their expression in a large clinically annotated DLBCL patient
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cohort (n= 424; GSE31312). Patients were diagnosed with de novo
DLBCL according to WHO criteria and were monitored as part of
the “International DLBCL Rituximab-CHOP Consortium Program
Study” in 29 medical centers58. Gene expression proﬁles were
generated prior to standard treatment with R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone). Notably,
we observed a signiﬁcant over-representation of predictors of poor
survival in the top 50 CIS list (p= 2.97 × 10−5, Fisher’s exact test):
for 11 genes, patients with cancers expressing low mRNA levels
had a signiﬁcantly reduced overall survival (Supplementary
Table 4). Effects on survival could also be observed in another,
albeit smaller, DLBCL cohort (n= 220; GSE10846) for 10 out
of these 11 genes. Kaplan–Meier plots displaying overall and
progression-free survival for the top ﬁve genes are shown in Fig. 8.
Among them is NR3C1, which codes for the glucocorticoid
receptor, a druggable gene (for information on the druggability of
other CIS genes see Supplementary Data 7). The glucocorticoid
prednisone is part of the standard treatment regime of different
hematopoietic cancer types. In T-cell acute lymphoblastic leukemia
resistance to glucocorticoid treatment has been previously
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associated with SNPs or deletions in NR3C159. Although genetic
alterations in NR3C1 are very rare in human DLBCLs, its
expression levels vary signiﬁcantly between patients. Finally, our
screen also discovered genes that are interacting with or down-
stream of Nr3c1, including the CIS genes Crebbp, Pou2f1, and
Hnrnpu, further supporting the relevance of this pathway in
DLBCL biology. Taken together, our discovery of Nr3c1 as a major
DLBCL CIS and its strong association with therapy response/
resistance establishes NR3C1 as a bona ﬁde tumor suppressor and
predictive marker in human DLBCL.
Discussion
Our work describes transposon and CRISPR tools/methods for
gene discovery as well as functional annotation of cancer gen-
omes. Their application provided comprehensive insights into the
molecular landscapes of DLBCL. We performed the ﬁrst BCL-
focused PB transposon screen and discovered large sets of DLBCL
drivers. More than half of these genes have not been found
earlier by other approaches to cancer genome analysis. This study
thus vastly expands the catalog of human DLBCL genes. Multiple
layers of evidence support the validity and importance of
the screening results, including (i) the enrichment of bona ﬁde
DLBCL tumor suppressors among the top-scoring genes in our
list (e.g., Gna13), (ii) the positive validation of discovered genes,
such as Rfx7 and Phip, which we show to indeed suppress lym-
phomagenesis in vivo, (iii) the integration of human data, which
showed that tumor suppressors identiﬁed in our screen are
indeed dysregulated in human DLBCL, and (iv) the discovery
of cancer genes with clinical relevance, including biomarkers
predicting treatment response and survival in human DLBCL.
All together, these data underline the power of our screening
approach to inform BCL biology.
Methods
Generation of mouse strains and cohorts. Constitutive PB transposase knock-in
mice (Rosa26PB), Blmm3 mice, and Eµ-myc transgenic mice have been described
earlier20,33,54.
To generate Rosa26Cas9 knock-in mice (Gt(ROSA)26Sortm1(Cas9)Rrad), we cloned
a human codon-optimized hemagglutinin-tagged Cas9 sequence derived from
Streptococcus pyogenes into a Gateway-compatible entry vector (Addgene
#1739860), which was then shuttled into a Rosa26-targeting Gateway destination
vector with loxP-ﬂanked puromycin resistance-containing stop cassette (modiﬁed
after Addgene #2118960). Embryonic stem cell (JM8) targeting, blastocyst
injections, and subsequent breeding steps were performed using standard
protocols/techniques. Upon generation of conditional Rosa26LSL-Cas9 knock-in
mice, we derived a constitutive Rosa26Cas9 mouse line by deletion of the loxP-
ﬂanked stop cassette in the germline. Rosa26LSL-Cas9 and Rosa26Cas9 mice were
Fig. 7 A CRISPR/Cas9-based in vivo platform for BCL functional genomics. a Outline of the functional genomic approach for in vivo gene validation.
b Kaplan–Meier plot showing survival of mice transplanted with hematopoietic stem/progenitor cells (HSPC) transduced with Trp53 sgRNA, Trp53 shRNA,
and non-targeting (NT) sgRNA. p < 0.0001 for both Trp53-sgRNA vs. NT-sgRNA and Trp53-shRNA vs. NT-sgRNA. p < 0.03 for Trp53-sgRNA vs. Trp53-
shRNA. p-values (log-rank test) were corrected for multiple testing using the Bonferroni method. c The transposon insertion pattern in Rfx7 predicts that
gene-disruption is the cancer-causing mechanism. Each arrow represents an individual insertion. Insertions from all DLBCLs in the cohort are shown. ITP2
transposons can trap genes in either orientation. Insertions are distributed over the whole length of the gene (predicting a tumor suppressor). There is no
bias for hot-spot areas of insertions as typically observed for unidirectional "activating" insertions in oncogenes. Consensus coding sequence (Rfx7-201) is
displayed. d Kaplan–Meier plot for mice transplanted with HSPCs transduced with Rfx7 sgRNA and NT sgRNA. p < 0.0001, log-rank test. e Transposon
insertion pattern in Phip, predicting tumor suppressive function of the gene. Consensus coding sequence (Phip-201) is shown. Each arrow represents
an individual insertion. Insertions from all DLBCLs in the cohort are shown. f Heatmap displaying copy number variations on human chromosome 6 in
samples from the TCGA-DLBC (n= 48) dataset (TCGA Research Network: http://cancergenome.nih.gov). The position of PHIP is indicated. g Function of
Phip as a B-cell lymphoma tumor suppressor was validated using the CRISPR/Cas9-based in vivo functional genomic approach. Kaplan–Meier plot for mice
transplanted with HSPCs transduced with Phip sgRNA and non-targeting (NT) sgRNA transplants. p < 0.0001, log-rank test. sgRNA single guide RNA,
EFS elongation factor 1-alpha core promoter, eGFP enhanced green ﬂuorescent protein, Mb megabase
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Fig. 8 Clinical relevance of CIS genes in human DLBCL. Association of CIS genes with overall and progression-free survival in a large clinically annotated
DLBCL patient cohort (n= 424; GSE31312). For each of the 50 CIS genes, the cohort was stratiﬁed into "low" (LE; below median expression) or "high"
expression (HE, above median). Kaplan–Meier plots for the top ﬁve genes, for which associations (between low gene expression and poor survival) were
also observed in a second DLBCL patient cohort (n= 220; GSE10846), are shown. The signiﬁcance threshold was set to a false discovery rate of 0.05. For
genes, for which multiple probes were available, the one giving the signal with the highest variance was selected. Association with overall survival (OS) is
shown on the top, and association with progression-free survival (PFS) on the bottom
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established and maintained on a pure C57BL/6 background. Genotyping primers
for Rosa26Cas9 knock-in mice are listed in Supplementary Data 8.
Transgenic transposon mouse lines harboring ITP1 and ITP2 transposons were
generated as delineated in Rad et al.20. Brieﬂy, ITP transposons were cut out of the
pBlueScript donor vector with appropriate restriction enzymes and prepared for
pronuclear injection using standard techniques. Founder animals were screened
for transposon integrations by Southern blot using an En2SA-speciﬁc probe.
Metaphases derived from the peripheral blood of the animals were prepared to
identify transposon donor loci by ﬂuorescence in situ hybridization (FISH) and
quantitative real-time PCR was conducted to determine the transposon copy
number in the founder mice with primer and probe sequences listed in
Supplementary Data 8. Founder animals were then crossed with C57BL/6 mice and
offspring was genotyped by PCR using previously described protocols28 with
primers listed in Supplementary Data 8. F2 animals were used to establish
transgenic transposon mouse lines and FISH analysis conﬁrmed transposon
integration sites in these animals after death on metaphases from spleen
preparations.
Experimental (ITP2-M;Rosa26PB/+;Blmm3/m3) and control (Rosa26PB/+;
Blmm3/m3 and ITP2-M;Blmm3/m3) mice were maintained on a mixed C57BL/6J x
129S1/SVImJ x FVB/NJ background.
Note that triple-transgenic ITP1-C;Rosa26PB/+;Blmm3/m3 mice showed
extensive embryonic lethality, which is primary linked to the large size of the ITP1
transposon concatemer (n= 70 copies) for following reasons: (i) Blmm3/m3 mice
are fertile and viable and develop no embryonic phenotypes33, excluding the
Blmm3/m3 allele as cause of the observed lethality, (ii) double transgenic ATP;
Rosa26PB/+ mice with transposon copy numbers similar to ITP1-C;Rosa26PB/+
mice showed comparable or even higher rates of embryonic lethality in a Bloom-
proﬁcient background20, and (iii) in ITP2-M;Rosa26PB/+;Blmm3/m3 mice, which
harbor half as much transposon copies, embryonic lethality is dramatically
reduced.
Mice were kept in the animal facilities of the Wellcome Trust Sanger Institute,
Hinxton/Cambridge, UK and Klinikum rechts der Isar, Technical University
Munich, München, Germany under speciﬁc-pathogen-free (SPF) conditions on a
12-h light/dark cycle, receiving food and water ad libitum. All animal experiments
were carried out in compliance with the requirements of the European guidelines
for the care and use of laboratory animals and were approved by the UK Home
Ofﬁce and the Institutional Animal Care and Use Committees (IACUC) of the
Technical University Munich (Regierung von Oberbayern, Munich, Germany).
Tests of splice acceptor elements. Gene trapping efﬁciency tests were performed
as described in Prosser et al.61. Brieﬂy, transposons carrying different splice
acceptor elements were cloned into a hypoxanthine phosphoribosyltransferase
(Hprt) exchange vector between a loxP and a lox511 cassette in both orientations.
These Hprt exchange vectors were electroporated individually together with a Cre
expression vector into male embryonic stem cells, which harbor an acceptor cas-
sette knock-in at the X-chromosomal Hprt locus. Recombinase-mediated cassette
exchange led to replacement of a resistance marker cassette (CMV-EM7-BSD-pA)
with the transposon-containing exchange cassette (elements between the loxP and
lox511 cassette in the Hprt vector). Embryonic stem cells were then selected with
6TG. Efﬁcient splicing by the splice acceptor within the transposon leads to a
premature termination of transcription resulting in a non-functional Hprt protein.
Hprt deﬁciency induces 6TG resistance. After selection, cells were stained with
crystal violet and 6TG-resistant colonies were counted.
Necropsy and histopathological analysis. All animals were monitored regularly
for signs of sickness (e.g., inactivity, palpable/visible masses, and poor grooming).
During necropsy, a gross inspection of all internal organs was carried out. For
DNA/RNA isolation, tissue samples were stored in RNAlater (Sigma). For histol-
ogy, tissue samples were ﬁxed in 4% formaldehyde overnight, parafﬁn-embedded,
sectioned, and stained using hematoxylin and eosin following standard protocols.
Experienced mouse hematopathologists, who were blinded to the mouse genotypes,
performed analysis of the tumors.
DNA and RNA isolation. DNA and RNA isolation of tissue samples was per-
formed according to manufacturer’s instructions using the Qiagen DNeasy Blood &
Tissue Kit and the Qiagen RNeasy Plus Mini Kit, respectively.
cDNA synthesis and real-time qPCR. cDNA synthesis was conducted using
SuperScript II Reverse Transcriptase (Thermo Fisher Scientiﬁc) according to
standard protocols. Real-time qPCR was conducted with SYBR™ Select Master Mix
(Thermo Fisher Scientiﬁc) and primers listed in Supplementary Data 9.
Immunohistochemistry. IHC was performed with antibodies directed against
B220/CD45R (RA3-6B2; R&D Systems; 1:40 dilution), CD138 (281-2; BD Bios-
ciences; 1:50 dilution), CD3 (A0452; DAKO; 1:100 dilution), myeloperoxidase
(A0398; DAKO; 1:100 dilution), Ki-67 (RM-9106-S1; Thermo Fisher Scientiﬁc;
1:200), Bcl6 (sc-858; Santa Cruz Biotechnology; 1:50), Irf4 (sc-6059; Santa Cruz
Biotechnology; 1:100), and Pten (M362729-2; Agilent; 1:150 dilution).
Pre-treatment of sections was conducted with EDTA for 20 min (B220, CD138,
CD3, myeloperoxidase), 30 min (Ki-67, Irf4, Pten), or 40 min (Bcl6).
We used goat anti-rabbit, rabbit anti-rat, rabbit anti-goat, and rabbit anti-
mouse secondary antibodies (AfﬁniPure Goat Anti-Rabbit IgG (H+L) [111-005-
003; Jackson ImmunoResearch], AfﬁniPure Rabbit Anti-Rat IgG [312-005-045;
Jackson ImmunoResearch], Rabbit Anti-Goat IgG [P0449; DAKO], and Rabbit
Anti-Mouse IgG [ab125904; Abcam]).
RNA sequencing. Library preparation for bulk 3′-sequencing of poly(A)-RNA was
done as described in Parekh et al.62. Brieﬂy, barcoded cDNA of each sample was
generated with a Maxima RT polymerase (Thermo Fisher Scientiﬁc) using oligo-dT
primer containing barcodes, unique molecular identiﬁers (UMI) and an adapter. 5′
ends of the cDNAs were extended by a template switch oligonucleotide (TSO).
After pooling of all samples, full-length cDNA was ampliﬁed with primers binding
to the TSO-site and the adapter. cDNA was tagmented with the Nextera XT kit
(Illumina) and 3′-end-fragments ﬁnally ampliﬁed using primers with Illumina P5
and P7 overhangs. In comparison to Parekh et al. (2016), the P5 and P7 sites were
exchanged to allow sequencing for the cDNA in read1 and barcodes and UMIs in
read2 to achieve a better cluster recognition. The library was sequenced on a
NextSeq 500 (Illumina) with 75 cycles for the cDNA in read1 and 16 cycles for the
barcodes and UMIs in read2.
The minor murine reference genome release GRCm38.p6 including all
haplotypes and patches was used as reference for mapping the raw read data with
Dropseq tools v1.13. Gencode annotation release M19 was used to determine read
counts per gene. The resulting genes x samples count matrix was imported into R
v3.4.4 and further processed with DESeq2 v1.8. Prior clustering, lowly expressed
genes were removed and the data were subsequently rlog transformed with a
parametric ﬁt and an intercept only design. Gene lists used for classiﬁcation of
samples were taken from Wright et al.40. Genes with murine orthologues were used
for clustering of rlog transformed expression data, using the Ward method for
cluster agglomeration. Z-transformed expression values are shown as heatmap.
B-cell receptor repertoire sequencing. Analysis of the immune repertoire of
murine diffuse large B-cell lymphoma samples was performed as described in
Turchaninova et al.63. with minor modiﬁcations, which allowed us to introduce
Illumina Nextera adapters and indexes during PCR64. Brieﬂy, 700 ng RNA
(extracted from whole tissue lysate) was transcribed into cDNA using a 5′ template
switch oligo (TSO), which contains a unique molecular identiﬁer. IGH and IGL
libraries were ampliﬁed using a set of IGHC-speciﬁc/IGLC-speciﬁc and 5′ TSO-
speciﬁc primers introducing indexed Nextera sequencing adapters (listed in Sup-
plementary Data 10). The resulting libraries were analyzed on the Illumina MiSeq
(300 bp paired end).
Analysis of the B-cell receptor repertoire. For analysis of the B-cell receptor
repertoire, raw data were demultiplexed using bcl2fastq. Unique molecular iden-
tiﬁer (UMI) tag extraction was performed using the CheckoutBatch command from
MIGEC 1.2.942 with options -cute and --overlap set and remaining parameters left
as default values. UMI-guided consensus assembly was conducted according to the
default settings of MIGEC in accordance with MIG statistics derived by the same
tool. This led to different MIG size thresholds used for different samples, with some
samples having a low threshold. For further analysis, only overlapping read pairs
were considered. IGH chain and IGL chain samples were analyzed separately using
MiXCR 2.1.12 software43. For each sample, reads were aligned to the mouse
reference sequences provided by MiXCR. The chain type for the heavy chain
samples was speciﬁed as “IGH” and for the light chain as “IGL,IGK”. To allow
downstream processing following non-default parameters were used: --save-
description, --save-reads, -p rna-seq, -OreadsLayout=Unknown. Clone assembly
was based on the CDR3 region. An index ﬁle was generated in the process;
-OsearchDepth parameter was set to 0. Information about the clones was exported
using the exportClones command and following non-default parameters: --preset
full, -cGenes, -o, -t (therefore excluding out-of-frame and stop codon containing
mutants) and -chains speciﬁed according to the sample type. Furthermore align-
ment information was exported using the exportAlignment command with para-
meters -descrR1, -readID, -vBestIdentityPercent and -cloneID set. For all subsequent
analyses, we further excluded clusters that were supported by a single unique UMI-
labeled cDNA molecule sequence. This was performed to increase the conﬁdence
of the ﬁnal clonality analysis, as most of the sequence subvariants which might
originate from errors obtained in the course of cDNA synthesis or from under-
corrected PCR and sequencing errors remaining after UMI consensus assembly
were removed63.
Generation of clonality network plots. For visualization of the clonal structures
of individual tumos, we developed CloNet, a pipeline for generation of clonality
network plots. Each dot in the plot represents a clone reported by MiXCR. The
size of the dot scales with the third root of the number of reads assigned to the
respective clone. Note that due to such scale the differences at high read counts
appear less pronounced than in the small and middle range. This deﬁnition was
necessary to enable visualization of the dominant clones in monoclonal samples,
which can accumulate more than 90% of all reads. Two clones were connected by a
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link if they map to at least one equal V and J gene and differ by only 1 bp in their
CDR3 sequence. A fully connected group of clones forms a clonal cluster. A clonal
cluster was highlighted by color if the cluster accumulated 10% or more of the
overall read counts of the sample.
Array comparative genomic hybridization. Array comparative genomic hybri-
dization (aCGH) was performed as described in Wolf et al.65. Brieﬂy, Agilent
oligonucleotide aCGH (Agilent 60 k mouse CGH arrays with a custom design
(AMADID 041078)) was conducted according to manufacturer’s instructions.
Agilent Genomic Workbench software version 7.0.4.0 was used for pre-processing
of aCGH data. For aberration calling, the ADM-2 algorithm was applied. Segment
coordinates were reported for the GRCm37 reference genome.
Quantitative transposon insertion site sequencing. QiSeq was performed as
described in Friedrich et al.28. Brieﬂy, DNA samples were sheared with a Covaris
AFA sonicator to a mean fragment length of 250 bp. The fragmented DNA was
then end-repaired, A-tailed, and a splinkerette adapter was ligated to each DNA
end. For the 5′ and 3′ transposon end, subsequent steps (ampliﬁcation and
sequencing of transposon–genome junctions) were conducted separately. The
speciﬁc structure of the splinkerette adapter (Y-shaped design with a template
and a hairpin strand) ensures that only transposon–genome junction fragments
(and not genomic fragments without transposon insert) can be ampliﬁed in the
following ﬁrst PCR step (which was conducted with transposon-speciﬁc and
splinkerette-speciﬁc primers). Afterwards, a second nested PCR step was per-
formed for further ampliﬁcation, barcoding of samples and extension with Illumina
ﬂow cell-binding sites P5 and P7. Each sample was then quantiﬁed with quanti-
tative real-time PCR (using P5-speciﬁc and P7-speciﬁc primers). Subsequently,
samples were equimolarly mixed and the library pool was again quantiﬁed.
Libraries were sequenced on the Illumina MiSeq sequencer (75 bp, paired-end).
Mapping of integrations to the mouse genome was performed using the SSAHA2
algorithm and sequences containing transposon–genome junctions were selected
for downstream analyses.
CIMPL analysis. For identiﬁcation of CIS (genomic regions that were more fre-
quently hit by transposons than expected by chance), ITP2 insertions with a read
coverage ≥20 were subjected to statistical analysis using CIMPL (Common
Insertion site Mapping PLatform) analysis, which is based on a Gaussian kernel
convolution framework50. Insertions within a 3 Mb region upstream and down-
stream of the transposon donor locus were excluded from the analysis (local
hopping area of the transposon as described in Rad et al.20). We used different scale
parameters (30,000, 50,000, 70,000, and 90,000) and only included CISs identiﬁed
across all scales and being supported by at least 10% of the samples in the analysis.
CISs were ranked according to the number of contributing tumor samples. Sﬁ1, a
known artifact frequently detected in insertional mutagenesis screens66, was
removed from the list of CIS genes.
TAPDANCE analysis. For TAPDANCE (Transposon Annotation Poisson Dis-
tribution Association Network Connectivity Environment) analysis51, ITP2 inser-
tions with a read coverage ≥2 were considered. As for CIMPL analysis, insertions 3
Mb region upstream and downstream of the donor locus on chromosome 14 were
excluded and Sﬁ1 was removed from the CIS gene list. All top 50 CIS genes
identiﬁed by CIMPL were also detected with TAPDANCE analysis.
Co-occurrence analysis. A Fisher's exact test was performed for co-occurrence
interference of the top 50 CIS genes. p-values were corrected for multiple testing
(Benjamini–Hochberg).
Cross-species analyses. Analyses were performed using the publicly available
datasets Reddy et al.4 and the TCGA DLBCL dataset (TCGA Research Network:
http://cancergenome.nih.gov).
Gene expression analyses. For gene expression analyses, datasets with the
accession numbers GSE12453 (only DLBCL and normal B cells (centroblasts) were
used for analysis), GSE12195 and GSE2350 were retrieved from the NCBI Gene
Expression Omnibus database. Raw data was normalized with RMA. Gene anno-
tations for each probe set were derived from the Ensembl v90 database. If multiple
probe sets represent the same gene, the probe set with the highest mean intensity
across all samples for a given dataset was used for further analyses. Differential
expression between conditions of interest were tested with limma. A gene was
considered to be signiﬁcant if the false discovery rate was <0.05 and the log2
expression change between conditions was at least 0.8.
Sequencing of regions with SNPs. A SNP (rs30424206)-containing region within
the mouse Pten gene was ampliﬁed and sequenced as described in Weber et al.67.
Brieﬂy, genomic CRISPR/Cas9 target regions were ampliﬁed with Q5® High-
Fidelity DNA Polymerase (New England Biolabs) using PCR primers listed in
Supplementary Data 9. PCR products were puriﬁed with the Monarch® PCR &
DNA Cleanup Kit (5 μg) (New England Biolabs). For library preparation, end
repair and A-tailing was performed (NEBNext® Ultra™ II DNA Library Prep Kit for
Illumina®, New England Biolabs) and an Illumina paired end adapter was ligated.
Individual samples were barcoded with eight cycles of PCR. Barcoded samples were
pooled and quantiﬁed with qPCR. The single pool was sequenced on the Illumina
MiSeq (300 bp, paired end). Raw reads were preprocessed with Trimmomatic v0.36
with the following parameter settings: leading/trailing Phred quality score cut-off:
25; minimum read length: 50 nt; minimum average Phred quality score within a
sliding window of 10 nt: 25. Forward and reverse reads passing these ﬁlters were
combined using Flash v.1.2.11. Merged reads were mapped to the mm10 mouse
reference genome following variant calling with BBMap (https://sourceforge.net/
projects/bbmap). Only variant positions with a coverage of at least 100 reads were
considered for downstream analyses.
Cell-culture-based competition assays. For in vitro knockdown experiments of
candidate genes, RFX7 and PHIP shRNAs and a scrambled control shRNA
(sequences listed in Supplementary Data 9) were cloned into a lentiviral pLKO.1
vector containing a U6 promoter-driven shRNA cassette and a blue ﬂuorescent
protein (BFP) driven by the phosphoglycerate kinase promoter. The GCB-DLBCL
cell line HT (ATCC® CRL-2260™) and the ABC-DLBCL cell line RIVA (ACC 585)
were cultivated according to distributor’s instructions and lentivirus production
was conducted according to standard protocols. For each shRNA construct, 5 × 105
cells were transduced with the respective lentiviral particles in a well of a 12-well-
plate using a spin infection protocol. For competition assays, transduced BFP-
positive cells were co-cultured with non-transduced cells in six-well-plates and the
proportion of BFP-positive cells was analyzed on day 3, 7, 10, 14, and 17 post
infection. Percentage of BFP-positive cells was normalized to day 3 post trans-
duction. For analysis of knockdown efﬁciencies, BFP-positive HT and RIVA cells
were sorted 17 days post infection. RFX7 and PHIP expression was determined by
real-time quantitative PCR (qPCR) using primers speciﬁc for RFX7 and PHIP
transcripts (sequences listed in Supplementary Data 9). For normalization of RNA
input, GAPDH qPCR (primers listed in Supplementary Data 9) was performed.
CRISPR/Cas9-based BCL in vivo validation platform. For the CRISPR/Cas9-
based BCL in vivo validation platform, sgRNA sequences for gene targeting were
selected with the Benchling CRISPR sgRNA design tool (https://benchling.com/
crispr). SgRNA oligonucleotides were cloned into the pLKO5.sgRNA.EFS.GFP
vector (Addgene #5782268). The plasmid contains a U6-driven sgRNA expression
cassette and the ﬂuorescence marker enhanced green ﬂuorescent protein (eGFP)
driven by the elongation factor 1-alpha core (EFS) promoter. Sequences of sgRNAs
are listed in Supplementary Data 9 and on-target editing efﬁciencies of all sgRNAs
were determined in in vitro cell culture systems before their use in vivo. Sequence
and vector used for the Trp53 short hairpin RNA (shRNA) experiments have been
published previously69.
Syngeneic transplantation experiments were conducted as described in Hoellein
et al.70. Brieﬂy, homozygous Rosa26Cas9/Cas9 and heterozygous Eµ-myc mice were
crossed and fetal liver cells (FLC) were isolated from double-transgenic Rosa26Cas9;
Eµ-myc embryos on day E13.5. FLCs were put into short-term culture and
transduced twice with pLKO5.sgRNA.EFS.GFP lentiviral particles in a 12-h interval.
24 h after the last infection, ﬂow cytometry was performed to determine the
percentage of eGFP-positive FLCs (usually ranging between 10% and 20%).
Syngeneic C57BL/6 recipient mice were irradiated (8.5 Gy) and 2.5 × 105 eGFP-
positive FLCs and 2 × 105 CD45.1 bone marrow cells (as support) were injected
into the lateral tail vein. Transplanted animals were monitored regularly for signs
of morbidity and lymphoma development. DNA was isolated from tumors for
insertion/deletion (indel) analyses and histological analyses of processed tumor
samples (which identiﬁed the cancers as lymphomas of B-cell origin) was
performed.
Note that as with other murine CRISPR/Cas models, the potential
immunogenicity of Cas9 has to be carefully considered. Therefore, use of Cas9
expressing recipient animals or inducible Cas9 systems might be advantageous.
Sequencing of CRISPR/Cas9 target regions. CRISPR/Cas9 target regions were
sequenced by Sanger capillary sequencing and amplicon-based NGS as described in
Weber et al.67. Brieﬂy, genomic CRISPR/Cas9 target regions were ampliﬁed with
Q5® High-Fidelity DNA Polymerase (New England Biolabs) using PCR primers
listed in Supplementary Data 9. PCR products were puriﬁed with the Monarch®
PCR & DNA Cleanup Kit (5 μg) (New England Biolabs). For library preparation,
end repair and A-tailing was performed (NEBNext® Ultra™ II DNA Library Prep
Kit for Illumina®, New England Biolabs) and an Illumina paired end adapter was
ligated. Individual samples were barcoded with eight cycles of PCR. Barcoded
samples were pooled and quantiﬁed with qPCR. The single pool was sequenced on
the Illumina MiSeq (300 bp, paired end). For processing of data and downstream
analysis, see “Sequencing of regions with SNPs”.
Flow cytometry. Flow cytometry data were acquired on a FACSCanto II ﬂow
cytometer (BD Biosciences) or CytoFLEX S (Beckmann Coulter) cytometer.
Sorting of cells was performed using a FACSARIA III cell sorter (BD Biosciences).
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FlowJo (Tree Star Inc.) and Kaluza Software (Beckmann Coulter) were used for
data analysis.
Survival analysis. Gene expression datasets with the accession numbers GSE31312
and GSE10846 were retrieved from the NCBI Gene Expression Omnibus database.
Raw data was normalized with VSN. Gene annotations and ﬁltering was performed
as described above. Gene expression was median stratiﬁed before being subjected to
log-rank testing with the R package survival v2.41-3. The false discovery rate was
calculated according to the Benjamini–Hochberg procedure.
Statistical analyses. All statistical analyses were performed using R v3.4.4.
Methods used for statistical hypothesis testing are directly stated in the text or
ﬁgure legends. In general, the signiﬁcance level was set to 0.05 and, if necessary,
correction for multiple testing was applied.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data have been deposited at EBI European Nucleotide Archive under accession
numbers PRJEB31030 and PRJEB31031.
Received: 7 June 2018 Accepted: 18 February 2019
References
1. Shaffer, A. L. III, Young, R. M. & Staudt, L. M. Pathogenesis of human B cell
lymphomas. Annu. Rev. Immunol. 30, 565–610 (2012).
2. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–86 (2015).
3. Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing
outcome in the context of clinical and biologic heterogeneity. Blood 125,
22–32 (2015).
4. Reddy, A. et al. Genetic and functional drivers of diffuse large B cell
lymphoma. Cell 171, 481–494, e15 (2017).
5. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell
lymphoma. Nat. Genet. 43, 830–837 (2011).
6. Okosun, J. et al. Integrated genomic analysis identiﬁes recurrent mutations
and evolution patterns driving the initiation and progression of follicular
lymphoma. Nat. Genet. 46, 176–181 (2014).
7. Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma.
N. Engl. J. Med. 378, 1396–1407 (2018).
8. Rossi, D. et al. The coding genome of splenic marginal zone lymphoma:
activation of NOTCH2 and other pathways regulating marginal zone
development. J. Exp. Med. 209, 1537–1551 (2012).
9. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from
structural and functional genomics. Nature 490, 116–120 (2012).
10. Kool, J. & Berns, A. High-throughput insertional mutagenesis screens in mice
to identify oncogenic networks. Nat. Rev. Cancer 9, 389–399 (2009).
11. Copeland, N. G. & Jenkins, N. A. Harnessing transposons for cancer gene
discovery. Nat. Rev. Cancer 10, 696–706 (2010).
12. Ivics, Z., Hackett, P. B., Plasterk, R. H. & Izsvak, Z. Molecular reconstruction
of Sleeping Beauty, a Tc1-like transposon from ﬁsh, and its transposition in
human cells. Cell 91, 501–510 (1997).
13. Cary, L. C. et al. Transposon mutagenesis of baculoviruses: analysis of
Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear
polyhedrosis viruses. Virology 172, 156–169 (1989).
14. Luo, G., Ivics, Z., Izsvak, Z. & Bradley, A. Chromosomal transposition of a
Tc1/mariner-like element in mouse embryonic stem cells. Proc. Natl Acad. Sci.
USA 95, 10769–10773 (1998).
15. Horie, K. et al. Efﬁcient chromosomal transposition of a Tc1/mariner-like
transposon Sleeping Beauty in mice. Proc. Natl Acad. Sci. USA 98, 9191–9196
(2001).
16. Ding, S. et al. Efﬁcient transposition of the piggyBac (PB) transposon in
mammalian cells and mice. Cell 122, 473–483 (2005).
17. Fischer, S. E., Wienholds, E. & Plasterk, R. H. Regulated transposition of a ﬁsh
transposon in the mouse germ line. Proc. Natl Acad. Sci. USA 98, 6759–6764
(2001).
18. Collier, L. S., Carlson, C. M., Ravimohan, S., Dupuy, A. J. & Largaespada, D.
A. Cancer gene discovery in solid tumours using transposon-based somatic
mutagenesis in the mouse. Nature 436, 272–276 (2005).
19. Dupuy, A. J., Akagi, K., Largaespada, D. A., Copeland, N. G. & Jenkins, N. A.
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty
transposon system. Nature 436, 221–226 (2005).
20. Rad, R. et al. PiggyBac transposon mutagenesis: a tool for cancer gene
discovery in mice. Science 330, 1104–1107 (2010).
21. Starr, T. K. et al. A transposon-based genetic screen in mice identiﬁes genes
altered in colorectal cancer. Science 323, 1747–1750 (2009).
22. Rad, R. et al. A conditional piggyBac transposition system for genetic
screening in mice identiﬁes oncogenic networks in pancreatic cancer.
Nat. Genet. 47, 47–56 (2015).
23. Mann, K. M. et al. Analyzing tumor heterogeneity and driver genes in single
myeloid leukemia cells with SBCapSeq. Nat. Biotechnol. 34, 962–972 (2016).
24. Berquam-Vrieze, K. E. et al. Cell of origin strongly inﬂuences genetic selection
in a mouse model of T-ALL. Blood 118, 4646–4656 (2011).
25. Giotopoulos, G. et al. A novel mouse model identiﬁes cooperating mutations
and therapeutic targets critical for chronic myeloid leukemia progression.
J. Exp. Med. 212, 1551–1569 (2015).
26. Zanesi, N. et al. A Sleeping Beauty screen reveals NF-kB activation in CLL
mouse model. Blood 121, 4355–4358 (2013).
27. Rahrmann, E. P. et al. Sleeping Beauty screen identiﬁes RREB1 and other genetic
drivers in human B-cell lymphoma. Mol. Cancer Res. 17, 567–582 (2018).
28. Friedrich, M. J. et al. Genome-wide transposon screening and quantitative
insertion site sequencing for cancer gene discovery in mice. Nat. Protoc. 12,
289–309 (2017).
29. Perez-Mancera, P. A. et al. The deubiquitinase USP9X suppresses pancreatic
ductal adenocarcinoma. Nature 486, 266–270 (2012).
30. Uren, A. G. et al. Large-scale mutagenesis in p19(ARF)- and p53-deﬁcient
mice identiﬁes cancer genes and their collaborative networks. Cell 133,
727–741 (2008).
31. Dave, B. J. et al. Cytogenetics and ﬂuorescence in situ hybridization studies of
diffuse large B-cell lymphoma in children and young adults. Cancer Genet.
Cytogenet. 153, 115–121 (2004).
32. Horn, H. et al. MYC status in concert with BCL2 and BCL6 expression
predicts outcome in diffuse large B-cell lymphoma. Blood 121, 2253–2263
(2013).
33. Luo, G. et al. Cancer predisposition caused by elevated mitotic recombination
in Bloom mice. Nat. Genet. 26, 424–429 (2000).
34. Patel, D. S., Misenko, S. M., Her, J. & Bunting, S. F. BLM helicase regulates
DNA repair by counteracting RAD51 loading at DNA double-strand break
sites. J. Cell Biol. 216, 3521–3534 (2017).
35. de la Rosa, J. et al. A single-copy Sleeping Beauty transposon mutagenesis
screen identiﬁes new PTEN-cooperating tumor suppressor genes. Nat. Genet.
49, 730–741 (2017).
36. Yusa, K. et al. Genome-wide phenotype analysis in ES cells by regulated
disruption of Bloom's syndrome gene. Nature 429, 896–899 (2004).
37. Suzuki, T., Minehata, K., Akagi, K., Jenkins, N. A. & Copeland, N. G. Tumor
suppressor gene identiﬁcation using retroviral insertional mutagenesis in Blm-
deﬁcient mice. EMBO J. 25, 3422–3431 (2006).
38. Hans, C. P. et al. Conﬁrmation of the molecular classiﬁcation of diffuse large
B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood
103, 275–282 (2004).
39. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identiﬁed
by gene expression proﬁling. Nature 403, 503–511 (2000).
40. Wright, G. et al. A gene expression-based method to diagnose clinically
distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA
100, 9991–9996 (2003).
41. Swerdlow, S. H. et al. The 2016 revision of the World Health Organization
classiﬁcation of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
42. Shugay, M. et al. Towards error-free proﬁling of immune repertoires.
Nat. Methods 11, 653–655 (2014).
43. Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity
proﬁling. Nat. Methods 12, 380–381 (2015).
44. Lossos, I. S. et al. Ongoing immunoglobulin somatic mutation in germinal
center B cell-like but not in activated B cell-like diffuse large cell lymphomas.
Proc. Natl Acad. Sci. USA 97, 10209–10213 (2000).
45. Omodei, D. et al. Expression of the brain transcription factor OTX1 occurs in
a subset of normal germinal-center B cells and in aggressive non-Hodgkin
lymphoma. Am. J. Pathol. 175, 2609–2617 (2009).
46. Taskinen, M. et al. Deregulation of COMMD1 is associated with poor
prognosis in diffuse large B-cell lymphoma. PLoS One 9, e91031 (2014).
47. Kwiecinska, A. et al. Ampliﬁcation of 2p as a genomic marker for
transformation in lymphoma. Genes Chromosomes Cancer 53, 750–768
(2014).
48. Green, M. R. et al. Transient expression of Bcl6 is sufﬁcient for oncogenic
function and induction of mature B-cell lymphoma. Nat. Commun. 5, 3904
(2014).
49. Moriarity, B. S. et al. A Sleeping Beauty forward genetic screen identiﬁes new
genes and pathways driving osteosarcoma development and metastasis. Nat.
Genet. 47, 615–624 (2015).
50. de Ridder, J., Uren, A., Kool, J., Reinders, M. & Wessels, L. Detecting
statistically signiﬁcant common insertion sites in retroviral insertional
mutagenesis screens. PLoS Comput. Biol. 2, e166 (2006).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09180-3
14 NATURE COMMUNICATIONS |         (2019) 10:1415 | https://doi.org/10.1038/s41467-019-09180-3 | www.nature.com/naturecommunications
51. Sarver, A. L., Erdman, J., Starr, T., Largaespada, D. A. & Silverstein, K. A.
TAPDANCE: an automated tool to identify and annotate transposon insertion
CISs and associations between CISs from next generation sequence data.
BMC Bioinforma. 13, 154 (2012).
52. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-
Hodgkin lymphoma. Nature 476, 298–303 (2011).
53. Muppidi, J. R. et al. Loss of signalling via Galpha13 in germinal centre B-cell-
derived lymphoma. Nature 516, 254–258 (2014).
54. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers
induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985).
55. Richter, J. et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma
identiﬁed by integrated genome, exome and transcriptome sequencing. Nat.
Genet. 44, 1316–1320 (2012).
56. De Semir, D. et al. Pleckstrin homology domain-interacting protein (PHIP) as
a marker and mediator of melanoma metastasis. Proc. Natl Acad. Sci. USA
109, 7067–7072 (2012).
57. Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are
associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24,
679–690 (2018).
58. Xu-Monette, Z. Y. et al. Mutational proﬁle and prognostic signiﬁcance of
TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report
from an International DLBCL Rituximab-CHOP Consortium Program Study.
Blood 120, 3986–3996 (2012).
59. Bokemeyer, A. et al. Copy number genome alterations are associated with
treatment response and outcome in relapsed childhood ETV6/RUNX1-
positive acute lymphoblastic leukemia. Haematologica 99, 706–714 (2014).
60. Hohenstein, P. et al. High-efﬁciency Rosa26 knock-in vector construction for
Cre-regulated overexpression and RNAi. Pathogenetics 1, 3 (2008).
61. Prosser, H. M., Rzadzinska, A. K., Steel, K. P. & Bradley, A. Mosaic
complementation demonstrates a regulatory role for myosin VIIa in actin
dynamics of stereocilia. Mol. Cell Biol. 28, 1702–1712 (2008).
62. Parekh, S., Ziegenhain, C., Vieth, B., Enard, W. & Hellmann, I. The impact of
ampliﬁcation on differential expression analyses by RNA-seq. Sci. Rep. 6,
25533 (2016).
63. Turchaninova, M. A. et al. High-quality full-length immunoglobulin proﬁling
with unique molecular barcoding. Nat. Protoc. 11, 1599–1616 (2016).
64. Davydov, A. N. et al. Comparative analysis of B-cell receptor repertoires
induced by live yellow fever vaccine in young and middle-age donors. Front.
Immunol. 9, 2309 (2018).
65. Wolf, M. J. et al. Metabolic activation of intrahepatic CD8+ T cells and
NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk
with hepatocytes. Cancer Cell 26, 549–564 (2014).
66. Quinlan, A. R. et al. Genome-wide mapping and assembly of structural variant
breakpoints in the mouse genome. Genome Res. 20, 623–635 (2010).
67. Weber, J. et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-
throughput functional cancer genomics in mice. Proc. Natl Acad. Sci. USA
112, 13982–13987 (2015).
68. Heckl, D. et al. Generation of mouse models of myeloid malignancy with
combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat.
Biotechnol. 32, 941–946 (2014).
69. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated
synthetic microRNA precursors. Nat. Genet. 37, 1289–1295 (2005).
70. Hoellein, A. et al. Myc-induced SUMOylation is a therapeutic vulnerability for
B-cell lymphoma. Blood 124, 2081–2090 (2014).
Acknowledgements
We thank Julia Eichinger, Anja Seemann, Teresa Stauber, Danijela Heide, and Olga
Seelbach for excellent technical assistance. J.d.l.R. was a recipient of a FEBS Long-Term
Fellowship during part of this work. M.A.T. and D.M.C. are supported by grant of the
Ministry of Education and Science of the Russian Federation (14.W03.31.0005), U.K. is
supported by Deutsche Krebshilfe (111305; 111944) and the German Research Foun-
dation (SFB 1335; project P3), J.C. is supported by the Fundación María Cristina
Masaveu Peterson, and R.R. is supported by Deutsche Krebshilfe (70112480), the Ger-
man Research Foundation (RA 1629/2-1; SFB1243; SFB 1321), and the German Cancer
Consortium Joint Funding Program.
Author contributions
G.S.V., J.C., A.B., and R.R. designed research; J.W., J.d.l.R., C.S.R., M.S., L.R., A.St., A.P.,
M.J.F., R.L., R.Ö., R.B., A.Sc., J.H., L.B.K., T.A., and F.Y. performed research, I.G.M., M.
M., U.Ko., G.J.H., K.S., and L.Q.-M. performed pathohistological analyses; M.A.T. and D.
M.C. developed mouse immunoglobulin proﬁling protocol; J.W., J.d.l.R., C.S.G., O.B., T.
E., M.G., G.L., G.S.V., J.C., A.B., and R.R. analyzed data; J.K., G.S., K.U., U.Z.-S., M.H., M.
S.-S., F.Y., D.S., P.L., and U.Ke. contributed analytic tools/reagents; J.W. and R.R. wrote
the paper.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09180-3.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks Ultan McDermott
and the other anonymous reviewer(s) for their contribution to the peer review of this
work. Peer reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
Julia Weber1,2, Jorge de la Rosa 3, Carolyn S. Grove3,4,5, Markus Schick6, Lena Rad3, Olga Baranov1,2,
Alexander Strong3, Anja Pfaus1,2, Mathias J. Friedrich1,2,3,7, Thomas Engleitner1,2, Robert Lersch 1,2,
Rupert Öllinger1,2, Michael Grau8,9, Irene Gonzalez Menendez10, Manuela Martella10, Ursula Kohlhofer10,
Ruby Banerjee3, Maria A. Turchaninova11,12,13, Anna Scherger6, Gary J. Hoffman3,4, Julia Hess14, Laura B. Kuhn15,
Tim Ammon2,6, Johnny Kim16,17, Günter Schneider7, Kristian Unger14, Ursula Zimber-Strobl15,
Mathias Heikenwälder 18, Marc Schmidt-Supprian2,6, Fengtang Yang 3, Dieter Saur2,7,19, Pentao Liu3,20,
Katja Steiger 21, Dmitriy M. Chudakov11,12,13,22,23, Georg Lenz8,9, Leticia Quintanilla-Martinez10, Ulrich Keller6,24,
George S. Vassiliou 3,25,26, Juan Cadiñanos 27,28, Allan Bradley3 & Roland Rad1,2,7,19
1Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München, Munich 81675, Germany.
2Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technische Universität München, Munich 81675, Germany.
3The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, UK. 4School of Medicine, University of Western Australia,
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09180-3 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1415 | https://doi.org/10.1038/s41467-019-09180-3 |www.nature.com/naturecommunications 15
Crawley 6009, Australia. 5Department of Haematology, PathWest and Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, Nedlands
6009, Australia. 6Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich 81675, Germany. 7Department of
Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich 81675, Germany. 8Department of Medicine A, University Hospital
Münster, Münster 48149, Germany. 9Cluster of Excellence EXC 1003, Cells in Motion, Münster 48149, Germany. 10Institute of Pathology and
Comprehensive Cancer Center, Eberhard Karls Universität Tübingen, Tübingen 72076, Germany. 11Laboratory of Genomics of Antitumor Adaptive
Immunity, Privolzhsky Research Medical University, Nizhny Novgorod 603005, Russia. 12Genomics of Adaptive Immunity Department, Shemyakin-
Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow 117997, Russia. 13Pirogov Russian National Research Medical
University, Moscow 117997, Russia. 14Helmholtz Zentrum München, Research Unit Radiation Cytogenetics, Neuherberg 85764, Germany.
15Helmholtz Zentrum München, Research Unit Gene Vectors, Munich 81377, Germany. 16Department of Cardiac Development and Remodeling,
Max-Planck-Institute for Heart and Lung Research, Bad Nauheim 61231, Germany. 17German Center for Cardiovascular Research (DZHK), Rhine
Main, Germany. 18Divison of Chronic Inﬂammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. 19German
Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. 20Li Ka Shing Faculty of Medicine, Stem Cell
and Regenerative Medicine Consortium, School of Biomedical Sciences, University of Hong Kong, Hong Kong, China. 21Comparative Experimental
Pathology, Technische Universität München, Munich 81675, Germany. 22Center of Life Sciences, Skolkovo Institute of Science and Technology,
Moscow 121205, Russia. 23Center of Molecular Medicine, CEITEC, Masaryk University, Brno 601 77, Czech Republic. 24Hematology and
Oncology–Campus Benjamin Franklin (CBF), Charité—Universitätsmedizin Berlin, Berlin 12203, Germany. 25Wellcome Trust-MRC Stem Cell
Institute, Cambridge Biomedical Campus, University of Cambridge, CB2 0XY, Cambridge, UK. 26Department of Haematology, Cambridge
University Hospitals NHS Trust, Cambridge CB2 0PT, UK. 27Instituto de Medicina Oncológica y Molecular de Asturias (IMOMA), Oviedo 33193,
Spain. 28Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de
Oviedo, Oviedo 33006, Spain. These authors contributed equally: Julia Weber, Jorge de la Rosa, Carolyn S. Grove. These authors jointly supervised
this work: George S. Vassiliou, Juan Cadiñanos, Allan Bradley, Roland Rad.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09180-3
16 NATURE COMMUNICATIONS |         (2019) 10:1415 | https://doi.org/10.1038/s41467-019-09180-3 | www.nature.com/naturecommunications
